Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes

What is the effect of oral semaglutide, 50 mg, compared with placebo on body weight and cardiometabolic risk factors in East Asian individuals with overweight or obesity, with or without type 2 diabetes?In this 68-week randomized clinical trial including 201 participants, oral semaglutide provided significantly greater body weight loss than placebo (estimated treatment difference, –13.1 percentage points) and improved cardiometabolic risk factors. The safety profile was consistent with the glucagon-like peptide-1 receptor agonist class.Oral semaglutide may be an effective treatment for overweight or obesity and associated complications in East Asian individuals.

Corresponding Authors: Takashi Kadowaki, MD, PhD, Toranomon Hospital, 2 Chrome-2-2, Toranomon, Minato-ku, Tokyo 105-8470, Japan (t-kadowaki@toranomon.kkr.or.jp); Kyoung-Kon Kim, MD, PhD, Gachon University College of Medicine, Gachon University Gil Medical Center, 21 Namdong-daero 774 beon-gil, Namdong-gu, Incheon, South Korea (zaduplum@gilhospital.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.